Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 27Lymphoma, Large B-Cell, Diffuse 26Burkitt Lymphoma 20Lymphoma, Follicular 14Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Neoplasms 7Lymphoma, B-Cell 6Recurrence 5Prostatic Neoplasms, Castration-Resistant 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, B-Cell, Marginal Zone 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Lymphoproliferative Disorders 3Hodgkin Disease 3Prostate Cancer Metastatic 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Leukemia 2Immunoblastic Lymphadenopathy 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

Prednisone 5Docetaxel 4niraparib 2enzalutamide 2darolutamide 2Pluvicto 2Abiraterone Acetate 2olaparib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1abiraterone 1Rosuvastatin Calcium 1Pioglitazone 1Omeprazole 1JNJ-64619178 1JNJ-64264681 1Dexamethasone 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × Prednisone × 90 days × Clear all
NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

MacroGenics

Phase 2 Completed
154 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT07225946 2026-05-11

KLK2-PASenger

Janssen Research & Development, LLC

Phase 3 Recruiting
800 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-05-08

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡